allogeneic– tag –
-
Clinical Progress of Engineered Cellular Immunotherapies for Autoimmunity: Diverse Modalities Pioneer New Treatment Avenues
PMC - NIH USA Overview Clinical development of engineered cellular immunotherapies for autoimmune diseases is rapidly advancing, poised to offer novel therapeutic options. Diverse modalities, including CAR-T cells, CAR-NK cells, and TCR-... -
CRISPR Cancer Therapy 2026: 32 Clinical Trials Underway, Gene-Edited T-Cells Face Efficacy and Off-Target Challenges
Hirschfeld Oncology USA Overview As of 2026, 32 clinical trials are investigating CRISPR-edited immunotherapies for cancer, predominantly focusing on ex vivo gene-edited immune cells. While these therapies generally demonstrate favorable... -
FDA Approves Orca-T Precision Treg Cell Therapy, Reducing Chronic GVHD Risk and Boosting Survival in Blood Cancer Patients Undergoing Matched Donor Transplants
AJMC (American Journal of Managed Care) USA Overview The U.S. FDA has approved Orca-T precision Treg cell therapy, designed to reduce the risk of chronic graft-versus-host disease (GVHD) and improve survival rates in blood cancer patient... -
Allogene Therapeutics’ Off-the-Shelf CAR-T Cema-cel Achieves 58.3% MRD Negativity in ALPHA3 Phase 2 LBCL Trial, Securing FDA RMAT and Fast Track Designations
Allogene Therapeutics, Inc. (Press Release) USA Overview Allogene Therapeutics announced strong Q2 2026 results, highlighting that its off-the-shelf CAR T-cell therapy, cema-cel, achieved a robust 58.3% minimal residual disease (MRD) neg... -
MD Anderson Researchers Identify Immature NK Cell Subpopulation in Donor Umbilical Cord Blood That Compromises CAR-NK Cell Therapy Antitumor Activity
Mirage News USA Overview Researchers at MD Anderson have discovered that a specific subpopulation of immature natural killer (NK) cells found in donor umbilical cord blood can diminish the antitumor activity of chimeric antigen receptor ... -
Sana Biotechnology Advances Hypoimmune iPSC-Derived SC451 for Type 1 Diabetes and In Vivo CAR T SG293 for Non-Hodgkin Lymphoma Towards Clinical Entry, Bolstered by NEJM Publication of Long-Term Pancreatic Islet Data
Sana Biotechnology, Inc. (Press Release) USA Overview Sana Biotechnology reported significant progress towards initiating clinical trials for SC451, an iPSC-derived pancreatic islet cell therapy for Type 1 diabetes, and SG293, an in vivo... -
Allogeneic Cell Therapy Manufacturing: Broad Applicability, Scalability, and Automation Driving Future Advances
Industry Informational Article USA Overview This article provides a comprehensive overview of allogeneic cell therapy manufacturing, highlighting its advantages over autologous approaches, including broader applicability, superior scalab... -
Liv Hospital Highlights Off-the-Shelf Allogeneic CAR-T Manufacturing for Enhanced Accessibility via Standardized Donor Cells
Liv Hospital Turkey Overview Liv Hospital is championing the development of allogeneic CAR-T cell manufacturing as an 'off-the-shelf' solution, leveraging standardized donor cells to significantly improve treatment accessibility. This ad... -
Off-the-Shelf Advantage: How Scalable Manufacturing Drives Clinical Success for Combination Cell Therapies
Industry Publication USA Overview A recent industry analysis underscores the critical role of manufacturability and scalability from the earliest stages of development for the clinical success of cell therapies, particularly complex comb... -
Lineage Cell Therapeutics Continues Support for Roche/Genentech’s OpRegen Cell Therapy, AlloSCOPE™ Platform Enables Scalable Manufacturing
Business Wire USA Overview Lineage Cell Therapeutics reported Q2 2026 financial results and business updates, confirming continued support for its OpRegen cell therapy development collaboration with Roche and Genentech, including technic...
